Multimedial tutorials - Dematepa: De Martinis Telemedicine Panel

Vai ai contenuti

Multimedial tutorials

Activity
06 Febbraio 2024
Large vessel intimal sarcoma
Angiosarcoma is a very rare neoplasm. Whenever it affects the large vessels (aorta, pulmonary artery, inferior cava vein, heart), it takes the name of Intimal Sarcoma. The intimal sarcoma is even rarer. A review of the literature and a case report are presented. Finally difficulties and pitfalls in early diagnosis are highlighted by the experts.
28 October 2023
Amiloidosi cardiaca (Essentials of cardiac amyloidosis)
Cardiac amyloidosis is not a rare disorder. It is easy to prompt the diagnosis only whenever the general practitioner suspect it. The differential diagnosis should be done chiefly against the hypertrophic miocardiopathy and the other restrictive filling pattern cardiopathies. Nowadays, new drugs are available to speed down the evolution of such disorder and prolong both life expectancy and quality.
09 March 2023
Unified and universal health systems and satusehat untuk semua (one health for all) in Indonesia. Special focus is given to Indonesia in this overview about unified and universal health systems. Indonesia is developing and implementing the platform satusehat (one health for all). Such application is available also for the patients’ mobiles and facilitates the health information exchange of the patient in the referral process between different levels of care. Several countries have been experiencing the development of unified and universal health systems. The models of Canada, Brazil and Italy are herewith reported and the Citizen’s Health Electronic Record of Italy is mentioned.
26 April 2022
Paxlovid, Remdesivir, Molnupiravir: anti-viral drugs against Sars-Cov-2.
Antiviral drugs against the SARS-CoV-2 virus have an exclusive indication in the phase of active viral replication, which corresponds to the first week of illness. Paxlovid and remdesivir have been provenly effective in educing the occurrence of complications such as the Severe Acute Respiratory Syndrome (ARDS) and reducing mortality through 28 days. On the other hand, Molnupiravir (Lagevrio) after the presentation of the data of the interim analysis, whereby the Merck company obtained the authorization for marketing by the Food and Drug Administration, did not resist criticism in the final analysis. This is why Molnupiravir is not held as a drug of first choice.
28 March 2022
Cardiopathy: vaccination against Sars-Cov-2 or exemption ? Myocarditis, pericarditis and even both may complicate common flu, Covid-19 and sometimes they are an adverse reaction to vaccination against SARS-Cov-2 virus, no matter the brand of the vaccine. Face to chronic heart diseases, the vaccinator may be puzzled whether it is of higher risk the vaccination or Covid-19 infection. The literature about epidemiology and severity of histological damages to the heart was reviewed and some practical advices given by some experts. The multimedia tutorial is complementary to the clinical review we made about SARS-COV-2 vaccination adverse reactions.
27 Februray 2022
Teleconference on heart disease in diabetics. The patient with metabolic syndrome (type 2 diabetes, diabetes with insulin resistance) must be monitored in terms of cardiovascular risk for the possibility of an accelerated deterioration of the aging process, in order to establish the necessary therapeutic corrective measures early. In the teleconference, opinions of endocrinologists-diabetologists, cardiologists and internal medicine specialists are compared.
Privacy Policy
Torna ai contenuti